Search Results - Eva Gonzalez-Barca

Refine Results
  1. 1

    Low-Dose PET/CT and Full-Dose Contrast-Enhanced CT at the Initial Staging of Localized Diffuse Large B-Cell Lymphomas by Aida Sabaté-Llobera, Montserrat Cortés-Romera, Santiago Mercadal, Javier Hernández-Gañán, Helena Pomares, Eva González-Barca, Cristina Gámez-Cenzano

    Get full text
    Article


  2. 2

    Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms by Eva Domingo-Domènech, Yolanda Benavente, Eva González-Barca, Carlos Montalban, Josep Gumà, Ramón Bosch, Sophia S. Wang, Qing Lan, Denise Whitby, Alberto Fernández de Sevilla, Nathaniel Rothman, Sílvia de Sanjosé

    Published in Haematologica (2007-11-01)
    Get full text
    Article


  3. 3

    Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma by Anas Younes, Gilles Salles, Giovanni Martinelli, Robert Gregory Bociek, Dolores Caballero Barrigon, Eva González Barca, Mehmet Turgut, John Gerecitano, Oliver Kong, Chaitali Babanrao Pisal, Ranjana Tavorath, Won Seog Kim

    Published in Haematologica (2017-12-01)
    Get full text
    Article


  4. 4

    Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease by Eva González-Barca, Eva Domingo-Domenech, Francisco Javier Capote, Jose Gómez-Codina, Antonio Salar, Alicia Bailen, Jose-María Ribera, Andres López, Javier Briones, Andres Muñoz, Maite Encuentra, Alberto Fernández de Sevilla

    Published in Haematologica (2007-11-01)
    Get full text
    Article


  5. 5

    PB2304: FIVE-YEAR SUBGROUP ANALYSIS OF TAFASITAMAB + LENALIDOMIDE FROM THE PHASE II L-MIND STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA by Johannes Duell, Pau Abrisqueta, Martin Dreyling, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Anna Marina Liberati, Kami Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  6. 6

    P1138: FIVE-YEAR EFFICACY AND SAFETY OF TAFASITAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY DLBCL: FINAL RESULTS FROM THE PHASE II L-MIND STUDY by Johannes Duell, Pau Abrisqueta, Marc Andre, Marinela Augustin, Gianluca Gaidano, Eva González Barca, Wojciech Jurczak, Nagesh Kalakonda, Anna Marina Liberati, Kami Maddocks, Tobias Menne, Zsolt Nagy, Olivier Tournilhac, Abhishek Bakuli, Aasim Amin, Konstantin Gurbanov, Gilles Salles

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  7. 7

    Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective,... by Javier Briones, Silvana Novelli, José A. García-Marco, José F. Tomás, Teresa Bernal, Carlos Grande, Miguel A. Canales, Antonio Torres, José M. Moraleda, Carlos Panizo, Isidro Jarque, Francisca Palmero, Miguel Hernández, Eva González-Barca, Dulce López, Dolores Caballero

    Published in Haematologica (2014-07-01)
    Get full text
    Article


  8. 8

    Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospec... by Javier Briones, Silvana Novelli, José A. García-Marco, José F. Tomás, Teresa Bernal, Carlos Grande, Miguel A. Canales, Antonio Torres, José M. Moraleda, Carlos Panizo, Isidro Jarque, Francisca Palmero, Miguel Hernández, Eva González-Barca, Dulce López, Dolores Caballero

    Published in Haematologica (2014-03-01)
    Get full text
    Article


  9. 9

    Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study by Jason Westin, Tycel J. Phillips, Amitkumar Mehta, Marc S. Hoffmann, Eva Gonzalez-Barca, Catherine Thieblemont, Mariana Bastos-Oreiro, Richard Greil, Sebastian Giebel, Michael C. Wei, Jue Wang, Reinhard Bucher, Jason Sit, Elicia Penuel, Enkhtsetseg Purev, Donald L. Yee, Juan Miguel Bergua-Burgues

    Published in Blood Advances (2025-05-01)
    Get full text
    Article


  10. 10

    Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study by Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, Laurie H. Sehn, David Belada, Chiara Ghiggi, Neil Chua, Eva González-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Christopher Bolen, Andrea Knapp, Gila Sellam, Tina Nielsen, Deniz Sahin, Umberto Vitolo, Marek Trněný

    Published in Haematologica (2021-08-01)
    Get full text
    Article


  11. 11

    European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma by Pier Luigi Zinzani, Lionel Karlin, John Radford, Dolores Caballero, Paul Fields, Martine E. D. Chamuleau, Francesco d’Amore, Corinne Haioun, Catherine Thieblemont, Eva González-Barca, Carlos Grande García, Peter W. Johnson, Gustaaf W. van Imhoff, Thomas Ng, Karen Dwyer, Franck Morschhauser

    Published in Haematologica (2016-10-01)
    Get full text
    Article


  12. 12

    Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes by Ángel Serna, Víctor Navarro, Gloria Iacoboni, Laia López, Juan-Manuel Sancho, Eva González-Barca, Alberto López-García, Raúl Córdoba, Adolfo Sáez, Ana Jiménez Ubieto, Ainara Ferrero, Tomás García, Ángela Sánchez, Cristina García, Marc Bosch, Alba Cabirta, Moraima Jiménez, Ana Marín-Niebla, Francesc Bosch, Pau Abrisqueta

    Published in Haematologica (2024-07-01)
    Get full text
    Article


  13. 13

    Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles

    Published in Haematologica (2021-08-01)
    Get full text
    Article


  14. 14

    R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study by Alejandro Martín, Eulogio Conde, Montserrat Arnan, Miguel A. Canales, Guillermo Deben, Juan M. Sancho, Rafael Andreu, Antonio Salar, Pedro García-Sanchez, Lourdes Vázquez, Sara Nistal, María-José Requena, Eva M. Donato, José A. González, Ángel León, Concepción Ruiz, Carlos Grande, Eva González-Barca, María-Dolores Caballero

    Published in Haematologica (2008-12-01)
    Get full text
    Article


  15. 15

    MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy by Alexandra Valera, Armando López-Guillermo, Teresa Cardesa-Salzmann, Fina Climent, Eva González-Barca, Santiago Mercadal, Íñigo Espinosa, Silvana Novelli, Javier Briones, José L. Mate, Olga Salamero, Juan M. Sancho, Leonor Arenillas, Sergi Serrano, Nadina Erill, Daniel Martínez, Paola Castillo, Jordina Rovira, Antonio Martínez, Elias Campo, Luis Colomo

    Published in Haematologica (2013-10-01)
    Get full text
    Article


  16. 16

    Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma by Johannes Duell, Kami J. Maddocks, Eva González-Barca, Wojciech Jurczak, Anna Marina Liberati, Sven de Vos, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Nagesh Kalakonda, Marc André, Martin Dreyling, Tobias Menne, Olivier Tournilhac, Marinela Augustin, Andreas Rosenwald, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet Ambarkhane, Gilles Salles

    Published in Haematologica (2021-07-01)
    Get full text
    Article


  17. 17

    R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group by Juan‐Manuel Sancho, Rubén Fernández‐Alvarez, Francisco Gual‐Capllonch, Esther González‐García, Carlos Grande, Norma Gutiérrez, María‐Jesús Peñarrubia, Ana Batlle‐López, Eva González‐Barca, José‐María Guinea, Eva Gimeno, Francisco‐Javier Peñalver, Miguel Fuertes, Mariana Bastos, José‐Ángel Hernández‐Rivas, José‐María Moraleda, Olga García, Marc Sorigué, Alejandro Martin

    Published in Cancer Medicine (2021-02-01)
    Get full text
    Article


  18. 18

    In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma by Montserrat Pérez-Salvia, Eneko Aldaba, Yosu Vara, Myriam Fabre, Cristina Ferrer, Carme Masdeu, Aizpea Zubia, Eider San Sebastian, Dorleta Otaegui, Pere Llinàs-Arias, Margalida Rosselló-Tortella, Maria Berdasco, Catia Moutinho, Fernando Setien, Alberto Villanueva, Eva González-Barca, Josep Muncunill, José-Tomás Navarro, Miguel A. Piris, Fernando P. Cossio, Manel Esteller

    Published in Haematologica (2018-11-01)
    Get full text
    Article


  19. 19

    Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma by Wyndham H. Wilson, Jacoline E.C. Bromberg, Maryalice Stetler-Stevenson, Seth M. Steinberg, Lourdes Martin-Martin, Carmen Muñiz, Juan Manuel Sancho, Maria Dolores Caballero, Marjan A. Davidis, Rik A. Brooimans, Blanca Sanchez-Gonzalez, Antonio Salar, Eva González-Barca, Jose Maria Ribera, Margaret Shovlin, Armando Filie, Kieron Dunleavy, Thomas Mehrling, Michele Spina, Alberto Orfao

    Published in Haematologica (2014-07-01)
    Get full text
    Article


  20. 20

    Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)Research... by Pau Abrisqueta, Eva González-Barca, Christelle Ferrà, Eduardo Ríos-Herranz, Margarita Fernández de la Mata, Julio Delgado, Rafael Andreu, José Ángel Hernández-Rivas, María José Terol, Almudena Navarro, M. Belén Vidriales, Patricia Baltasar, Javier De la Serna, Ángel Ramírez, Carmen Ballester, Carol Moreno, José Antonio García-Marco, Raúl Córdoba, Lucrecia Yáñez, Luís Felipe Casado, Marcos González, Francesc Bosch

    Published in EClinicalMedicine (2024-07-01)
    Get full text
    Article


Search Tools: